Stoke is pioneering a new way to treat the underlying cause of severe genetic epilepsies by precisely upregulating protein expression utilizing antisense oligonucleotide (ASOs) medicines. Our platform, Targeted Augmentation of Nuclear Gene Output (TANGO), allows us to deliver disease-modifying therapies in a highly precise, controlled, and durable manner.